Pharmstandard of the enterprise. Jsc "pharmaceuticalstandard". Interaction with other medicinal products

Registration number: LS-002525-060314
Trade name of the drug: Piperazine
INN: piperazine adipate
Chemical name: hexahydropyrazine adipate
Dosage form: pills
Composition for one tablet
Active substance: piperazine adipate - 0.5 g;
Excipients: potato starch - 0.077 g, talc - 0.018 g, gelatin (medical gelatin) - 0.005 g.
Description. Tablets are white, flat-cylindrical, beveled and scored.
Pharmacotherapeutic group: anthelmintic agent.
ATX code: .

Pharmacological properties

Pharmacodynamics
Has a paralyzing effect on nematodes (roundworms, pinworms), disrupting the function of their neuromuscular system, causing muscle paralysis. The severity of deworming with the drug is at the level of 90-95%, and with repeated use it can be about 100%. Due to the fact that piperazine does not destroy ascaris, there is no danger of absorption of biological toxic products of their decay. The drug is low-toxic.
Pharmacokinetics
The drug is rapidly absorbed from the gastrointestinal tract. It is excreted from the body mainly by the kidneys.

Indications for use: ascariasis and enterobiasis.

Method of administration and dosage

Inside. In the treatment of ascariasis, the drug is prescribed for two consecutive days, 2 times a day 1 hour before or 0.5-1 hour after meals in the following doses: adults and children from 15 years old - 1.5 g - 2.0 g; children aged 3 to 5 years - 0.5 g (daily dose 1.0 g), from 5 to 8 years old - 0.75 g (daily dose 1.5 g), from 8 to 12 years old - 1.0 g (daily dose 2.0 g), from 13 to 15 years old - 1.5 g (daily dose 3.0 g), It is possible to use the drug once within one day at a dose of 0.5 g to 4.0 g, depending on from age.
The maximum daily dose in adults is 4.0 g.
With enterobiasis in the same doses, the drug is prescribed for 5 consecutive days (1-3 courses of therapy are performed with a 7-day break between courses) or for one day, once at a dose of 0.5 g to 4.0 g, depending on age In between cycles, an enema is prescribed at night to mechanically wash out pinworms (adults 4-5 glasses of water, children 1-2 glasses with the addition of 1/2 teaspoon of sodium bicarbonate per glass of water).

Side effect

Rarely there is nausea, abdominal pain, headache that quickly disappear. Patients with renal failure may experience neurotoxic complications (muscle weakness, tremor, euphoria, hallucinations, blurred vision, impaired coordination of movements).

Contraindications

Organic diseases of the central nervous system... Hypersensitivity. Chronic renal failure, pregnancy and lactation. Childhood up to 3 years (for a given dosage).

Overdose

In case of an overdose, unexpressed muscle weakness, tremors, neurotoxic phenomena are observed, especially in patients with impaired renal excretory function. Overdose relief measures: removal of the drug from the stomach and intestines (gastric lavage, artificial vomiting, use of saline laxatives, enemas, use of intestinal adsorbents - activated carbon), symptomatic treatment. If necessary, oxygen and transfusion therapy is performed. Thiamine is administered for neurological symptoms.

special instructions

No preliminary preparation of patients is required. During treatment, strict adherence to the hygienic regime is necessary. Laxatives are prescribed only for patients with a tendency to constipation in the evening (on piperazine days). The safety of the drug during pregnancy and lactation has not been established.

Influence on the ability to drive vehicles, mechanisms

The drug does not affect the ability to manage vehicles and various mechanisms, as well as to engage in other potentially hazardous activities that require increased attention and speed of mental and motor reactions.

Interaction with other medicinal products

Strengthens the severity of extrapyramidal disorders caused by chlorpromazine.

RELEASE FORM
Tablets 0.5 g.
10 or 20 tablets in a blister strip packaging. 10 tablets in a contoured cell-free package.
30, 50 or 100 tablets in a polymer jar.
1, 2, 3 or 5 contour packs or a polymer can together with instructions for use are placed in a pack.
It is allowed to place contour cell or non-cell packaging with an equal number of instructions for use in a group packaging.

Shelf life 5 years. After the expiration date, the drug should not be used.

Storage conditions
Store at a temperature not exceeding 25 ° C.
Keep out of the reach of children.

The holding is huge and heterogeneous, as luck would have it. For some, luck is to kick the bulldozer, for someone - to develop and work in a good team. There are departments for both the first and the second. The "fields" are also different. Don't judge by hr, they are weird here)

There are a huge number of characters with a universal ego and negative efficiency. And the budget for their maintenance is a kind of charity in favor of people with mental disabilities.

07.11.19 18:14 Moscow cityEmployee,

Office next to the metro.

The vacancy of the analyst is updated from time to time, it hangs constantly. At the interview, it is positioned that analysts work here for a long time. The head of the department says this very pathetically. A stupid mindfulness test for third graders. Lack of feedback.

01.10.19 13:48 in the Moscow regionCoca Cola,

a good VHI, if you do not take into account dentistry, according to which you can only do ultrasonic cleaning of your teeth once a year white salary on a VTB or Sberbank card, that's all

gossip and cronyism. if you came on an ad, no career growth you may not even dream. I will tell you separately about the position of "Project Administrator" with Comrade IB Zyryanov. If you value yourself at least a gram, run away from here, I'm serious. At the interview, everyone colorfully tells: what a wonderful team in IT (lies, everyone is watching and knocking on Zyryanova to ...

21.03.19 11:48 Moscow cityLelya Krok,

Nice office

This was the first place I was asked when I was going to have my third child. And I had a lot of interviews. It was tempting to ask if they asked such questions to men. In addition, they have 3 or 4 stages of interviews. At the same time, the vacancy has been hanging for more than six months for sure. They spoke downwardly (mainly the head of the department, HR is still nothing). They tortured me for a long time about my life path ...

26.10.18 22:15Moscow cityCustomer,

26.10.18 22:13Moscow cityCustomer,

Feedback from the buyer. Medicines are mostly fake. Mukaltin, what the hell, will not do anyone any good and harm too. The tablets are pure soda. That Mukaltin, which we are treating for coughs and does not smell. They sell just pressed soda. Advice: do not buy medicines from this company! This is a dummy!

13.09.18 15:43 in the Moscow regionFormer employee,

Stable company, salary is not delayed, there are bonuses, voluntary medical insurance is normal, especially for executive positions, corporate parties, canteen, sometimes they can even be sent to study for courses (rarely). A great opportunity for growth - if, of course, you did not come from the street, but a relative or friend of someone from the leadership. The director at Pharmstandard LLC Darko Y. is smart, knowledgeable and decent, it's a pity that there are two deputies for them, ...

If you are an ordinary employee, there is little good, especially in the purchasing department of an LLC, there are two deputies Mashnikova and Strigulin. authoritarian communication style. If you are a decent person and a professional, it will be difficult for you here, because loyalty must be portrayed very strongly, ...

05.02.18 16:21 Moscow cityMasha Anastasia,

She worked for more than six months. Leadership: Podgorbunskikh N.I., Usmanova E. and Gr-ka Tolstova - complete inadequate. They do not know what they want from employees, they are rude, they bring to tears. They took on one position, the responsibilities turned out to be completely different. Sneaky spying on people, a report on your work every day about your every step (when you went to the toilet, ate, sat on the Internet) Low and disgusting, and this, for a minute ...

(ISIC: 21)

Equity Turnover ▲ 55.9 billion rubles. (2013, IFRS) Operating profit ▲ 23.4 billion rubles. (2013, IFRS) Net profit ▲ 11.9 billion rubles. (2013, IFRS) Assets Number of employees ▲ 5.5 thousand people (year 2013) Parent company Augment Investments Ltd. Site pharmstd.ru

Production capacity

The aggregate production capacity allows the company to produce more than 1.7 billion packages per year. The production facilities of the Pharmstandard group of companies are provided by 9 factories for the production of medicines:

Russia Russia: Kursk, JSC "Pharmstandard-Leksredstva"
Russia Russia: Ufa, JSC "Pharmstandard-UfaVITA"
Russia Russia: Tomsk, JSC "Pharmstandard-Tomskkhimfarm"
Russia Russia: Moscow region, JSC "Biomed" them. I. I. Mechnikova
Russia Russia: Moscow, LLC "PHARMAPARK"
Russia Russia: Vladimir region, CJSC "Lekko"
Russia Russia: Tyumen, JSC "TZMOI"
Ukraine Ukraine: Kharkiv, PJSC "Pharmstandard-Biolek"
Singapore Singapore: Bever pharmaceutical PTE Ltd

History

Pharmstandard was founded in 2003 by Profit House (a Millhouse Capital structure that managed the assets of Roman Abramovich). By this time, the company owned only two Russian pharmaceutical plants: Fitofarm-NN in Nizhny Novgorod and "Ufavita" in Ufa. Five more were bought from the American pharmaceutical giant ICN Pharmaceuticals: October in St. Petersburg, Marbiopharm in Yoshkar-Ola, Leksredstva in Kursk, Polypharm in Chelyabinsk and Tomskkhimfarm in Tomsk.

Subsequently, three plants were sold or closed for various reasons: Oktyabr (inconveniently located in the very center of the city), Marbiopharm (focused on the secondary production of substances for Pharmstandard's strategy), Polypharm (required too much investment).

In 2005, Pharmstandard bought the Tyumen plant of medical equipment and instruments.

By 2006 to bring production to conformity international standards GMP quality, the company spent more than $ 70 million.

In 2006, Pharmstandard bought the Masterlek company, which had 15 famous brands... In particular, the rights to Arbidol, Amiksin and Flucostat were obtained. By this time, the holding's production capacity exceeded 1 billion packs per year; Pharmstandard plants produced all forms of drugs (tablets, suspensions, capsules, sprays). By the end of the year, Arbidol came out on top in sales in Russia, displacing hawthorn tincture.

In 2006, the company launched several more high-tech drugs into production: the first growth hormone in Russia, Rastan, developed at the Institute of Bioorganic Chemistry, and the genetically engineered human insulin Biosulin. On this moment Pharmstandard is the largest Russian insulin producer. The company's capacity would be enough to meet 100% of the needs of Russians for this drug, but Russia still imports most of its insulin from abroad.

Since 2007, Pharmstandard has been actively working with foreign partners: for example, at Tomskkhimpharm, together with Solvay Pharma (France), the production of IRS19 and Imudon has been launched.

In 2008, Pharmstandard signed an agreement with the Latvian company Grindeks (Latvia) for the exclusive distribution and promotion of the drug Mildronate, masters the production of Afobazol, and introduces the genetically engineered drug Neipomax into production.

In 2009, Pharmstandard became the first and the only Russian member of the International Council of Producers, Distributors and Consumers of Active Pharmaceutical Ingredients (excipients) in Europe (IPEC Europe). In the same year, the company implemented an operation to implement a specialized IP solution for the central office and factories.

In 2009, Pharmstandard became the first Russian full member of the International Pharmaceutical Excipients Council Europe (IPEC Europe).

In 2010 year State corporation Rostec and Pharmstandard OJSC signed a cooperation agreement.

In 2010, Pharmstandard announces the acquisition of 100% of the shares of CJSC Vindexpharm.

in 2011, Pharmstandard announces the acquisition of 55% of shares in PJSC Biolek (Ukraine).

In 2011, Pharmstandard was recognized as the most influential Russian pharmaceutical manufacturer.

In 2012, Pharmstandard OJSC announces that the enterprises of Pharmstandard-UfaVITA OJSC and Pharmstandard-Leksredstva OJSC have joined the Association of Pharmaceutical Manufacturers of the Eurasian Economic Community.

In 2012, Pharmstandard OJSC acquired 50.1% of Bigpearl Trading Ltd. and 100% CJSC LEKKO. The investment amount did not exceed $ 80 million.

In 2013, Pharmstandard OJSC bought 100% of Singapore-based Bever pharmaceutical PTE Ltd for $ 590 million.

In 2018, Pharmstandard OJSC becomes one hundred percent owner of the PET-technology network of nuclear medicine centers, having bought out the remaining 49.9% from Rusnano. The deal amounted to 2.9 billion rubles.

In August 2018, Pharmstandard entered into an agreement with the American biopharmaceutical company Gilead (Gilead Sciences) on the production of Sovaldi (Sofosbuvir) drugs for the treatment of chronic hepatitis C and Truvada (Tenofovir / emtricitabine) for the treatment of HIV at Pharmstandard facilities.

Owners and management

General manager- Grigory Potapov. Chairman of the Board of Directors - Viktor Kharitonin.

The main owner of the company is Augment Investments Ltd (54.32%, owned by Viktor Kharitonin and Egor Kulkov), 9.68% of shares are traded on the MICEX and the RTS, 27.56% in the form of GDRs - on the London Stock Exchange. In March 2008, Roman Abramovich, Evgeny Shvidler and Millhouse Capital Management, who previously owned large stakes in the company, withdrew from its capital.

Primary placement

On May 4, 2007, during an Initial Public Offering (IPO), the company placed its shares in the Russian Trading System(RTS) and Global Depository Receipts (GDR) on the London Stock Exchange (LSE). Investors showed interest in the company's shares, and the placement took place at the upper limit of the established range - $ 58.2 per share and $ 14.55 per depositary receipt. The company's capitalization following the IPO was $ 2.2 billion.

Pharmstandard has placed on the Russian and London stock exchanges 40% of authorized capital, having bailed out $ 880 million before the option was exercised. Citi and UBS Investment Bank were the global co-coordinators of the placement.

Pharmstandard is the first Russian pharmaceutical company whose shares are quoted on international market.

Activity

By the beginning of 2013, Pharmstandard owned seven pharmaceutical plants and one plant for the production of medical equipment and instruments. The company's factories produce more than 250 names of medicines (more than 120 names are included in the List of Vital Drugs (VED)). The company's capacity is over 1.7 billion packages per year.

Pentalgin tablet

Pharmstandard-Ufavita in Ufa. The plant was founded in 1916. General Director - Vladimir Kreyman. The number of employees is 1400 people. Major brands: Complivit, Biosulin, Rastan, Neypomax, Phosphogliv.
Pharmstandard-Fitofarm-NN in Nizhny Novgorod
Pharmstandard-Tomskkhimfarm in Tomsk. The plant was founded in 1913. General Director - Andrey Skorokhod. The number of employees is over 600 people. Major brands: Arbidol, Amiksin, Imudon, Thermikon, IRS-19.
Pharmstandard-Leksredstva in Kursk. The plant was founded in 1922. General Director - Evgeny Prokhoda. The number of employees is over 1450 people. Major brands: Arbidol, Pentalgin, Phosphogliv.
Tyumen plant of medical equipment and instruments. The plant was founded in 1962. General Director - Alexander Nizovtsev. The main specialization of the plant is medical products for single use (needles, syringes, droppers, catheters, urinals), sterilization equipment (steam sterilizers), water distillers, water collectors.

The Pharmstandard group of companies produces more than 250 types of drugs, including drugs for the treatment of cardiovascular diseases, diabetes mellitus, growth hormone deficiency, gastroenterological, neurological, infectious diseases, metabolic disorders, oncological and other diseases.

Performance indicators

2013 - 55.92 billion rubles. (growth in comparison with 2012 by 8.8%);
2012 - 51.391 billion rubles. (growth in comparison with 2011 by 20.5%);
2011 - 42.653 billion rubles. (growth compared to 2010 by 43.7%);
2010 - 29.694 billion rubles. (growth in comparison with 2009 by 23.2%);
2009 - 24.096 billion rubles. (growth in comparison with 2008 by 68.1%).

Net profit in different years was:

2012 - 9.96 billion rubles. (an increase of 12.8%);
2011 - 8.832 billion rubles. (an increase of 23.3%);
2010 - 7.163 billion rubles. (an increase of 4.5%);
2009 - 6.852 billion rubles. (up 96%).

Export

Pharmstandard exports products to 16 countries:

The strategic plans include the expansion and development of the business in:

Venezuela, Argentina, Nicaragua, Nigeria, Egypt, Iran, Iraq, Afghanistan, UAE.

According to the results of 2012, export sales of the company's pharmaceutical products increased by 41.1% and amounted to RUB 1,320.9 million compared to RUB 935.9 million in 2011.

Awards and ratings

The drug Arbidol, which is part of the company's portfolio, took 1st place in sales in 2007 at Russian market over-the-counter drugs

All production facilities of the company fully meet the requirements Russian standards... 8 production sites of Pharmstandard-Leksredstva OJSC are certified according to the European Union Good Manufacturing Practice standards. industrial practice). The management of the company approved a program for the transition of factories to European GMP standards.

Principles

Strategy

Social responsibility

In its activities, the company adheres to the following fundamental principles:

Innovation - the fastest introduction of new scientific developments in medicine and pharmacology in close cooperation with domestic and foreign scientists.

Efficiency - conducting business processes based on an effective, harmonious combination of scientific and technical innovations and rich experience accumulated by the company over the years of intensive activity in the pharmaceutical market.

A responsibility- the use of international management and technological standards within the framework of the company's responsibility to the consumer. Compliance with environmental standards and reduction of industrial impact on environment taking into account the responsibility to future generations.

Strategic directions of the company's development

Development of and the introduction of new drugs, expanding the range of dosage forms and dosages of manufactured drugs to maximize the satisfaction of market needs and consumer expectations

Gain the depth of localization of drug production in joint projects with leading foreign pharmaceutical companies

Increase share of high-margin drugs in the company's nomenclature portfolio

Extension participation of the company in the state import substitution program

Automation production planning processes in order to improve the efficiency of process management and strengthen cost control

As part of the strategic development directions, the company makes significant investments in the development and modernization of production facilities.

Pharmstandard - the undisputed leader of the domestic pharmaceutical industry - guarantees consumers the highest quality standard of manufactured drugs.

The principles of social policy of the company are brought in line with public policy Russia in the field of drug supply, which provides for the replacement of expensive imported drugs with affordable domestic drugs produced in compliance with international standards. Pharmstandard cares about the safety of its products and the health of consumers. To this end, the company has organized a Pharmacovigilance system aimed at collecting and studying information on side effects and drug interactions, as well as effective interaction with regulatory authorities in this area.

As a socially responsible company Pharmstandard regularly provides targeted support socially unprotected categories of the population, as well as institutions in need of material support social sphere... The company highly appreciates the trust of doctors and patients in medicines, produced under the Pharmstandard trademark, and continues to invest in the development of new drugs and improvement of production technologies.

: PHST , RTS: PHST , MICEX: PHST

Year of foundation Location

Russia: Dolgoprudny, Moscow region

Key figures

Victor Kharitonin (chairman of the board of directors), Igor Krylov (general director)

Industry Turnover

▲ 42.66 billion rubles. (2011, IFRS)

Net profit

▲ 8.83 billion rubles. (2011, IFRS)

Site

History

Pharmstandard was founded in 2003 by Profit House (a Millhouse Capital structure that managed the assets of Roman Abramovich). By that time, the company owned only two Russian pharmaceutical plants: Fitofarm-NN in Nizhny Novgorod and Ufavita in Ufa. Five more were bought from the American pharmaceutical giant ICN Pharmaceuticals: Oktyabr in St. Petersburg, Marbiopharm in Yoshkar-Ola, Leksredstva in Kursk, Polypharm in Chelyabinsk and Tomskkhimfarm in Tomsk.

In 2005, Pharmstandard bought the Tyumen plant of medical equipment and instruments.

By 2006, the company spent more than $ 70 million to bring production to conformity with international GMP quality standards.

In 2006, Pharmstandard bought the Masterlek company, which had 15 well-known brands in its assets. In particular, the rights to Arbidol, Amiksin and Flucostat were obtained. By this time, the holding's production capacity exceeded 1 billion packs per year; Pharmstandard plants produced all forms of drugs (tablets, suspensions, capsules, sprays). By the end of the year, Arbidol came out on top in sales in Russia, overtaking Viagra and hawthorn tincture.

In 2006, the company launched several more high-tech drugs into production: the first growth hormone in Russia, Rastan, developed at the Institute of Bioorganic Chemistry, and the genetically engineered human insulin Biosulin. At the moment, Pharmstandard is the largest Russian insulin producer. The company's capacity would be enough to meet 100% of the needs of Russians for this drug, but Russia still imports most of its insulin from abroad.

Since 2007, Pharmstandard has been actively working with foreign partners: for example, Tomskkhimpharma, together with Solvay Pharma (France), launched the production of IRS19 and Imudon.

Owners and management

The main owner of the company is Augment Investments Ltd (57%, owned by Viktor Kharitonin and Egor Kulkov), 18% of shares are traded on the MICEX and the RTS, 25% in the form of GDRs - on the London Stock Exchange. In March 2008, Roman Abramovich, Evgeny Shvidler and Millhouse Capital Management, who previously owned large stakes in the company, withdrew from its capital.

Primary placement

On May 4, 2007, during an Initial Public Offering (IPO), the company placed its shares on the Russian Trading System (RTS) and Global Depository Receipts (GDRs) on the London Stock Exchange (LSE). Investors showed interest in the company's shares, and the placement took place at the upper limit of the established range - $ 58.2 per share and $ 14.55 per depositary receipt. The company's capitalization following the IPO was $ 2.2 billion.

Pharmstandard placed 40% of its authorized capital on the Russian and London stock exchanges, having raised $ 880 million before the option was exercised. Citi and UBS Investment Bank were the global co-coordinators of the placement.

Pharmstandard is the first Russian pharmaceutical company to be listed on the international market.

Activity

By the beginning of 2010, Pharmstandard owned four pharmaceutical plants and one plant for the production of medical equipment and instruments. The company's factories produce more than 240 names of medicines (about 90 names are included in the List of Vital Drugs (VED)). The company's capacity is more than 1.3 billion packs per year.

Pentalgin tablet

Pharmstandard-Ufavita in Ufa. The plant was founded in 1916. General Director - Vladimir Kreyman. The number of employees is 1400 people. Major brands: Complivit, Biosulin, Rastan, Neypomax, Phosphogliv.
Pharmstandard-Fitofarm-NN in Nizhny Novgorod
Pharmstandard-Tomskkhimfarm in Tomsk. The plant was founded in 1913. General Director - Pavel Smachkov. The number of employees is over 600 people. Major brands: Arbidol, Amiksin, Imudon, Thermikon, IRS-19.
Pharmstandard-Leksredstva in Kursk. The plant was founded in 1922. General Director - Evgeny Prokhoda. The number of employees is over 1450 people. Major brands: Arbidol, Pentalgin, Phosphogliv.
Tyumen plant of medical equipment and instruments. The plant was founded in 1962. General Director - Alexander Nizovtsev. The main specialization of the plant is medical products for single use (needles, syringes, droppers, catheters, urinals), sterilization equipment (steam sterilizers), water distillers, water collectors.

Performance indicators

The company's revenue in 2007 amounted to 11.3 billion rubles. (in 2006 - 8.5 billion rubles, an increase of 22%), net profit - 3.2 billion rubles. (RUB 2 billion)